Asia Pacific Metastatic Cancer Drugs Market Forecast to 2028

Asia Pacific Metastatic Cancer Drugs Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Cancer Type (Breast Cancer, Lung Cancer, Liver Cancer, Hematological Cancer, Brain Cancer, Prostate Cancer, Pancreatic Cancer, and Others), Route of Administration (Intravenous and Intramuscular), Drug Class (HER2 Inhibitors, Immune Checkpoint Inhibitors, PARP Inhibitors, Kinase Inhibitors, and Others), Product (Branded, Generics, and Biosimilars), and End User (Hospital, Specialty Clinic, and Others)

Report Code : BMIRE00025358 | Region : Asia Pacific | Industry : Pharmaceuticals | Published Date : 15/Jul/2022

The Asia Pacific metastatic cancer drugs market is expected to reach US$ 11,626.26 million by 2028 from US$ 7,985.76 million in 2021; it is estimated to grow at a CAGR of 5.5% from 2021 to 2028.

Advancements in artificial intelligence (AI) are anticipated to transform every industry. In drug discovery and development, time and costs required are key challenges to sustain the drug development pipeline. The development of oncology therapeutics is estimated to cost over US$ 2.6 billion to the manufacturer and take over a decade. These soaring costs are mostly a result of money invested in the 90% of candidate therapies that fail to enter the late stages of drug development, i.e., between phase 1 trials and regulatory approval. AI is projected to be the foundation for rapid, cheap, and efficient drug discovery and development. The integration of AI technology in cancer care could improve the accuracy and speed of diagnosis, aid in improved clinical decision-making, and lead to better health outcomes. AI-guided clinical care can play an important role in reducing health disparities, particularly in low-resource settings. Notably, the application areas of AI are expanding to include new approaches for cancer detection, screening, diagnosis and classification; cancer genomics characterization; tumor microenvironment analysis; and predictive and prognostic biomarkers assessment. AI can enhance many processes that are directly and indirectly related to the drug discovery and development. It can be used for improved tumor classification, computer-aided organic synthesis, compound discovery, assay development, and biomarker and target discovery. In general, AI aims to automate and optimize slow processes to substantially speed up the R&D drug discovery process. Several pharmaceutical, biotech, and software companies are making efforts to integrate AI into drug discovery and development. In 2016, Pfizer partnered with IBM Watson Health, an AI platform provider, to enhance its search for immuno-oncology treatments. Sanofi joined forces with Exscientia, the spin-out of Dundee University, to discover metabolic-disease therapies. Thus, the increased use of AI in drug development and delivery would create significant opportunities for the growth of the metastatic cancer drug market during the forecast period.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the metastatic cancer drugs market growth in the coming years. The market is expected to grow at a good CAGR during the forecast period.

Asia Pacific Metastatic Cancer Drugs Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Metastatic Cancer Drugs Market Segmentation

The market for Asia Pacific metastatic cancer drugs market is segmented into cancer type ,route of administration ,drug class , product , and end user. Based on cancer type, the market is segmented into breast cancer, lung cancer, liver cancer, haematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. Based on route of administration, the market is bifurcated into intravenous and intramuscular. Based on drug class, the Asia Pacific metastatic cancer drugs market is segmented into HER2 inhibitors, immune checkpoint inhibitors, parp inhibitors, kinase inhibitors, and others. Based on product, the market is segmented into branded, generics, and biosimilars. Based on end user, the market is segmented into hospital, specialty clinic, and others. By country, the Asia Pacific metastatic cancer drugs market is segmented into China, Japan, India, Australia, South Korea, and Rest of Asia Pacific.

Asia Pacific Metastatic Cancer Drugs Market – Companies Mentioned

AbbVie Inc. ; Amgen Inc. ; Bristol-Myers Squibb Company ; F. HOFFMANN-LA ROCHE LTD.; Novartis AG ; Astrazeneca ;Eli Lilly and Company; MERCK KGaA ; Pfizer Inc. (Arena Pharmaceutical GmbH) ; and Johnson and Johnson Services, Inc. are among the leading companies in the Asia Pacific metastatic cancer drugs market .

PARP Inhibitors segment has the Largest Share of Drug Class in the Asia Pacific Metastatic Cancer Drug Market during 2019-2028

According to our latest study on “Asia Pacific Metastatic Cancer Drug Market Forecast to 2028 - COVID-19 Impact and Analysis - by Cancer Type, Route of Administration, Drug Class, Product, End User” the market is projected to reach US$ 11,626.26 million by 2028 from US$ 7,985.76 million in 2021; it is expected to grow at a CAGR of 5.5% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the high prevalence of cancer and government initiatives to support developments in cancer treatment. However, complex technological process and high initial investment is hamper the market growth.

Based on drug class, has been segmented into HER2 inhibitors, immune checkpoint inhibitors, PARP inhibitors, kinase inhibitors, and others. In 2021, the PARP inhibitors segment accounted for the largest share of the market; it is further expected to continue its dominance over the forecast period. This class of drugs are used to prevent the cell from damage repair and dies. Thus, it helps in the slowing down the growth of cancer cells and prevents from spreading to other body parts. On the other hand, HER2 inhibitors drug class segment is expected to register the highest CAGR in the metastatic cancer drugs market during 2021-2028.

AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., Novartis AG, Astrazeneca, Eli Lilly and Company, MERCK KGaA, Pfizer Inc. (Arena Pharmaceutical GmbH), Johnson and Johnson Services, Inc., are among the leading companies in the Asia Pacific metastatic cancer drug market .The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.

The market for Asia Pacific metastatic cancer drugs market is segmented into cancer type, route of administration, drug class, product, and end user. Based on cancer type, the Asia Pacific metastatic cancer drugs market is segmented into breast cancer, lung cancer, liver cancer, hematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. Based on route of administration, the market is segmented into intravenous, and intramuscular. Based on drug class, the market is segmented into HER2 inhibitors, immune checkpoint inhibitors, parp inhibitors, kinase inhibitors, and others. Based on product, the Asia Pacific metastatic cancer drugs market is segmented into branded, generics and biosimilars. Based on end user, the Asia Pacific metastatic cancer drugs market is segmented into hospital, specialty clinic, and others. By country, the Asia Pacific metastatic cancer drugs market is segmented into China, Japan, India, Australia, South Korea and Rest of Asia Pacific.

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Asia Pacific Metastatic Cancer Drugs Market – By Cancer Type

1.3.2 Asia Pacific Metastatic Cancer Drugs Market – By Route of Administration

1.3.3 Asia Pacific Metastatic Cancer Drugs Market – By Drug Class

1.3.4 Asia Pacific Metastatic Cancer Drugs Market – By Product

1.3.5 Asia Pacific Metastatic Cancer Drugs Market – By End User

1.3.6 Asia Pacific Metastatic Cancer Drugs Market – By Country

2. Asia Pacific Metastatic Cancer Drugs Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Asia Pacific Metastatic Cancer Drugs Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 Asia Pacific– PEST Analysis

4.3 Expert Opinion

5. Asia Pacific Metastatic Cancer Drugs Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 High Prevalence of Metastatic Cancer

5.1.2 Government Initiatives to Support Developments in Cancer Treatment

5.2 Market Restraints

5.2.1 High Cost of Oncology Drugs

5.3 Market Opportunities

5.3.1 Investments in Artificial Intelligence for Oncology Drug Development

5.4 Future Trends

5.4.1 Increase in Launch of Metastatic Cancer Drugs

5.5 Impact analysis

6. Asia Pacific Metastatic Cancer Drugs Market – APAC Analysis

6.1 Asia Pacific Metastatic Cancer Drugs Market Revenue Forecast and Analysis

6.1.1 Asia Pacific Metastatic Cancer Drugs Market,- Forecast and Analysis

7. Asia Pacific Metastatic Cancer Drug Market Analysis – By Cancer Type

7.1 Overview

7.2 Asia Pacific Metastatic Cancer Drug Market Revenue Share, by Cancer Type (2021 and 2028)

7.2.1 Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type, 2019–2028 (USD Million)

7.3 Breast Cancer

7.3.1 Overview

7.3.2 Breast Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.4 Lung Cancer

7.4.1 Overview

7.4.2 Lung Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.5 Liver Cancer

7.5.1 Overview

7.5.2 Liver Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.6 Hematological Cancer

7.6.1 Overview

7.6.2 Hematological Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.7 Brain Cancer

7.7.1 Overview

7.7.2 Brain Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.8 Prostate Cancer

7.8.1 Overview

7.8.2 Prostate Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.9 Pancreatic Cancer

7.9.1 Overview

7.9.2 Pancreatic Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.10 Others

7.10.1 Overview

7.10.2 Others: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8. Asia Pacific Metastatic Cancer Drug Market – By Route of Administration

8.1 Overview

8.2 Asia Pacific Metastatic Cancer Drug Market, by Route of Administration, 2021 and 2028 (%)

8.2.1 Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration, 2019–2028 (USD Million)

8.3 Intravenous

8.3.1 Overview

8.3.2 Intravenous: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Intramuscular

8.4.1 Overview

8.4.2 Intramuscular: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8.5 Oral

8.5.1 Overview

8.5.2 Oral: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8.6 Others

8.6.1 Overview

8.6.2 Others: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9. Asia Pacific Metastatic Cancer Drug Market – By Drug Class

9.1 Overview

9.2 Asia Pacific Metastatic Cancer Drug Market, by Drug Class, 2021 and 2028 (%)

9.2.1 Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

9.3 HER2 Inhibitors

9.3.1 Overview

9.3.2 HER2 Inhibitors: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.4 Immune Checkpoints Inhibitors

9.4.1 Overview

9.4.2 Immune Checkpoints Inhibitors: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.5 PARP Inhibitors

9.5.1 Overview

9.5.2 PARP Inhibitors: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.6 Kinase Inhibitors

9.6.1 Overview

9.6.2 Kinase Inhibitors: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.7 Others

9.7.1 Overview

9.7.2 Others: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

10. Asia Pacific Metastatic Cancer Drug Market – By Product

10.1 Overview

10.2 Asia Pacific Metastatic Cancer Drug Market, by Product, 2021 and 2028 (%)

10.2.1 Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

10.3 Branded

10.3.1 Overview

10.3.2 Branded: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

10.4 Generics and Biosimilars

10.4.1 Overview

10.4.2 Generics and Biosimilars: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

11. Asia Pacific Metastatic Cancer Drug Market – By End User

11.1 Overview

11.2 Asia Pacific Metastatic Cancer Drug Market, by End User, 2021 and 2028 (%)

11.2.1 Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

11.3 Hospital

11.3.1 Overview

11.3.2 Hospitals: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

11.4 Specialty Clinic

11.4.1 Overview

11.4.2 Specialty Clinics: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

11.5 Others

11.5.1 Overview

11.5.2 Others: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

12. Asia Pacific Metastatic Cancer Drugs Market – Regional Analysis

12.1 Asia Pacific: Asia Pacific Metastatic Cancer Drugs Market

12.1.1 Overview

12.1.2 Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by Country, 2021 & 2028 (%)

12.1.2.1 China: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.2.1.1 China: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.2.1.2 China: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type, 2019–2028 (USD Million)

12.1.2.1.3 China: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration, 2019–2028 (USD Million)

12.1.2.1.4 China: Asia Pacific Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.1.2.1.5 China: Asia Pacific Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.1.2.1.6 China: Asia Pacific Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.1.2.2 Japan: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.2.2.1 Japan: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.2.2.2 Japan: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type– Revenue and Forecast to 2028 (USD Million)

12.1.2.2.3 Japan: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration, 2019–2028 (USD Million)

12.1.2.2.4 Japan: Asia Pacific Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.1.2.2.5 Japan: Asia Pacific Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.1.2.2.6 Japan: Asia Pacific Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.1.2.3 India: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.2.3.1 India: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.2.3.2 India: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type, 2019–2028 (USD Million)

12.1.2.3.3 India: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration, 2019–2028 (USD Million)

12.1.2.3.4 India: Asia Pacific Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.1.2.3.5 India: Asia Pacific Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.1.2.3.6 India: Asia Pacific Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.1.2.4 Australia: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.2.4.1 Australia: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.2.4.2 Australia: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type, 2019–2028 (USD Million)

12.1.2.4.3 Australia: Asia Pacific Metastatic Cancer Drug Market, By Route of Administrations, 2019–2028 (USD Million)

12.1.2.4.4 Australia: Asia Pacific Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.1.2.4.5 Australia: Asia Pacific Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.1.2.4.6 Australia: Asia Pacific Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.1.2.5 South Korea: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.2.5.1 South Korea: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.2.5.2 South Korea: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type, 2019–2028 (USD Million)

12.1.2.5.3 South Korea: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration, 2019–2028 (USD Million)

12.1.2.5.4 South Korea: Asia Pacific Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.1.2.5.5 South Korea: Asia Pacific Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.1.2.5.6 South Korea: Asia Pacific Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.1.2.6 Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.2.6.1 Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.2.6.2 Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type, 2019–2028 (USD Million)

12.1.2.6.3 Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration, 2019–2028 (USD Million)

12.1.2.6.4 Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.1.2.6.5 Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.1.2.6.6 Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

13. Asia Pacific Metastatic Cancer Drug Market –Industry Landscape

13.1 Overview

13.2 Growth Strategies in the Asia Pacific Metastatic Cancer Drug Market, 2021-2028

13.3 Inorganic Developments

13.3.1 Overview

13.4 Organic Growth Strategies

13.4.1 Overview

14. Company Profiles

14.1 AbbVie Inc.

14.1.1 Key Facts

14.1.2 Business Description

14.1.3 Products and Services

14.1.4 Financial Overview

14.1.5 SWOT Analysis

14.1.6 Key Developments

14.2 Amgen Inc.

14.2.1 Key Facts

14.2.2 Business Description

14.2.3 Products and Services

14.2.4 Financial Overview

14.2.5 SWOT Analysis

14.2.6 Key Developments

14.3 Bristol-Myers Squibb Company

14.3.1 Key Facts

14.3.2 Business Description

14.3.3 Products and Services

14.3.4 Financial Overview

14.3.5 SWOT Analysis

14.3.6 Key Developments

14.4 F. HOFFMANN-LA ROCHE LTD.

14.4.1 Key Facts

14.4.2 Business Description

14.4.3 Products and Services

14.4.4 Financial Overview

14.4.5 SWOT Analysis

14.4.6 Key Developments

14.5 Novartis AG

14.5.1 Key Facts

14.5.2 Business Description

14.5.3 Products and Services

14.5.4 Financial Overview

14.5.5 SWOT Analysis

14.5.6 Key Developments

14.6 Astrazeneca

14.6.1 Key Facts

14.6.2 Business Description

14.6.3 Products and Services

14.6.4 Financial Overview

14.6.5 SWOT Analysis

14.6.6 Key Developments

14.7 Eli Lilly and Company.

14.7.1 Key Facts

14.7.2 Business Description

14.7.3 Products and Services

14.7.4 Financial Overview

14.7.5 SWOT Analysis

14.7.6 Key Developments

14.8 MERCK KGaA

14.8.1 Key Facts

14.8.2 Business Description

14.8.3 Products and Services

14.8.4 Financial Overview

14.8.5 SWOT Analysis

14.8.6 Key Developments

14.9 Pfizer Inc. (Arena Pharmaceutical GmbH)

14.9.1 Key Facts

14.9.2 Business Description

14.9.3 Products and Services

14.9.4 Financial Overview

14.9.5 SWOT Analysis

14.9.6 Key Developments

14.10 Johnson and Johnson Services, Inc.

14.10.1 Key Facts

14.10.2 Business Description

14.10.3 Products and Services

14.10.4 Financial Overview

14.10.5 SWOT Analysis

14.10.6 Key Developments

15. Appendix

15.1 About The Insight Partners

15.2 Glossary of Terms

LIST OF TABLES.

Table 1. Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, – Revenue and Forecast to 2028 (USD Million)

Table 2. Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 3. Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 4. Asia Pacific Asia Pacific Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

Table 5. Asia Pacific Asia Pacific Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

Table 6. Asia Pacific Asia Pacific Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 7. China: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 8. China: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 9. China: Asia Pacific Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

Table 10.   China: Asia Pacific Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 11.   China: Asia Pacific Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 12.   Japan: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type– Revenue and Forecast to 2028 (USD Million)

Table 13.   Japan: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration– Revenue and Forecast to 2028 (USD Million)

Table 14.   Japan: Asia Pacific Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 15.   Japan: Asia Pacific Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 16.   Japan: Asia Pacific Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 17.   India: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type– Revenue and Forecast to 2028 (USD Million)

Table 18.   India: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration– Revenue and Forecast to 2028 (USD Million)

Table 19.   India: Asia Pacific Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 20.   India: Asia Pacific Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 21.   India: Asia Pacific Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 22.   Australia: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 23.   Australia: Asia Pacific Metastatic Cancer Drug Market, By Route of Administrations – Revenue and Forecast to 2028 (USD Million)

Table 24.   Australia: Asia Pacific Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 25.   Australia: Asia Pacific Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 26.   Australia: Asia Pacific Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 27.   South Korea: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 28.   South Korea: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 29.   South Korea: Asia Pacific Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

Table 30.   South Korea: Asia Pacific Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 31.   South Korea: Asia Pacific Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 32.   Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, By Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 33.   Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, By Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 34.   Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

Table 35.   Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 36.   Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 37.   Recent Inorganic Growth Strategies in the Asia Pacific Metastatic Cancer Drug Market

Table 38.   Recent Organic Growth Strategies in the Asia Pacific Metastatic Cancer Drug Market

Table 39.   Glossary of Terms, Asia Pacific Metastatic Cancer Drugs Market

LIST OF FIGURES.

Figure 1. Asia Pacific Metastatic Cancer Drugs Market Segmentation

Figure 2. Asia Pacific Metastatic Cancer Drugs Market Overview

Figure 3. The PARP Inhibitors Segment Held The Largest Share of Drug Class Segment in Asia Pacific Metastatic Cancer Drugs Market

Figure 4. China Is Expected to Show Remarkable Growth During the Forecast Period

Figure 5. Asia Pacific PEST Analysis

Figure 6. Expert Opinion

Figure 7. Asia Pacific Metastatic Cancer Drugs Market Impact Analysis of Driver and Restraints

Figure 8. Asia Pacific Metastatic Cancer Drugs Market – Revenue Forecast and Analysis – 2021- 2028

Figure 9. Asia Pacific Metastatic Cancer Drug Market Revenue Share, by Cancer Type (2021 and 2028)

Figure 10.   Breast Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 11.   Lung Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 12.   Liver Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 13.   Hematological Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 14.   Brain Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 15.   Prostate Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 16.   Pancreatic Cancer: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 17.   Others: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 18.   Asia Pacific Metastatic Cancer Drug Market, by Route of Administration, 2021 and 2028 (%)

Figure 19.   Intravenous: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 20.   Intramuscular: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 21.   Oral: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 22.   Others: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 23.   Asia Pacific Metastatic Cancer Drug Market, by Drug Class, 2021 and 2028 (%)

Figure 24.   HER2 Inhibitors: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 25.   Immune Checkpoints Inhibitors: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26.   PARP Inhibitors: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 27.   Kinase Inhibitors: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 28.   Others: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 29.   Asia Pacific Metastatic Cancer Drug Market, by Product, 2021 and 2028 (%)

Figure 30.   Branded: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 31.   Generics and Biosimilars: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 32.   Asia Pacific Metastatic Cancer Drug Market, by End User, 2021 and 2028 (%)

Figure 33.   Hospitals: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 34.   Specialty Clinics: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 35.   Others: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 36.   Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by Key Country – Revenue (2021) (USD Million)

Figure 37.   Asia Pacific: Asia Pacific Metastatic Cancer Drug Market, by Country, 2021 & 2028 (%)

Figure 38.   China: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 39.   Japan: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 40.   India: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 41.   Australia: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 42.   South Korea: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 43.   Rest of Asia Pacific: Asia Pacific Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 44.   Growth Strategies in the Asia Pacific Metastatic Cancer Drug Market, 2021-2028

The List of Companies - Asia Pacific Metastatic Cancer Drugs Market

● AbbVie Inc.                                                                                                        

● Amgen Inc.                                                                                                         

● Bristol-Myers Squibb Company                                                                 

● F. HOFFMANN-LA ROCHE LTD.                                                                   

● Novartis AG                                                                                                       

● Astrazeneca                                                                                                      

● Eli Lilly and Company                                                                                     

● MERCK KGaA                                                                                                    

● Pfizer Inc. (Arena Pharmaceutical GmbH)                                             

● Johnson and Johnson Services, Inc.

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific Metastatic Cancer Drugs Market.

● Highlights key business priorities in order to assist companies to realign their business strategies.

● The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific Metastatic Cancer Drugs Market, thereby allowing players across the value chain to develop effective long-term strategies.

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

● Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.

● Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TOP